| Date | Time | Source | Headline | Symbol | Company |
| 10/24/2023 | 4:32PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTRS | Viatris Inc |
| 10/24/2023 | 4:30PM | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:VTRS | Viatris Inc |
| 10/23/2023 | 9:00AM | PR Newswire (US) | Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row | NASDAQ:VTRS | Viatris Inc |
| 10/20/2023 | 5:18PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTRS | Viatris Inc |
| 10/20/2023 | 5:00PM | PR Newswire (US) | Rajiv Malik to Retire as President of Viatris Effective April 1, 2024 | NASDAQ:VTRS | Viatris Inc |
| 10/18/2023 | 8:00AM | PR Newswire (US) | Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking | NASDAQ:VTRS | Viatris Inc |
| 10/10/2023 | 9:29AM | PR Newswire (US) | Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023 | NASDAQ:VTRS | Viatris Inc |
| 10/05/2023 | 7:19AM | IH Market News | Thursday’s Wall Street Highlights: Orchard Therapeutics, Exxon Mobil, Alphabet, Ford, and more | NASDAQ:VTRS | Viatris Inc |
| 10/03/2023 | 7:35AM | Dow Jones News | Challenge to Novo Nordisk Obesity Drug Patents Rejected in US | NASDAQ:VTRS | Viatris Inc |
| 10/02/2023 | 5:23PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTRS | Viatris Inc |
| 10/02/2023 | 7:01AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTRS | Viatris Inc |
| 10/01/2023 | 5:00PM | PR Newswire (US) | Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA | NASDAQ:VTRS | Viatris Inc |
| 09/27/2023 | 8:58AM | Dow Jones News | Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops | NASDAQ:VTRS | Viatris Inc |
| 09/27/2023 | 8:00AM | PR Newswire (US) | Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tr | NASDAQ:VTRS | Viatris Inc |
| 09/12/2023 | 2:45PM | PR Newswire (US) | Viatris Named to TIME's World's Best Companies 2023 List | NASDAQ:VTRS | Viatris Inc |
| 09/05/2023 | 5:00AM | PR Newswire (US) | Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV | NASDAQ:VTRS | Viatris Inc |
| 08/07/2023 | 4:18PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:VTRS | Viatris Inc |
| 08/07/2023 | 7:38AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTRS | Viatris Inc |
| 08/07/2023 | 6:59AM | PR Newswire (US) | Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] | NASDAQ:VTRS | Viatris Inc |
| 08/07/2023 | 6:54AM | PR Newswire (US) | Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis | NASDAQ:VTRS | Viatris Inc |
| 07/31/2023 | 6:59AM | PR Newswire (US) | Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva | NASDAQ:VTRS | Viatris Inc |
| 07/14/2023 | 5:45AM | PR Newswire (US) | VTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023 | NASDAQ:VTRS | Viatris Inc |
| 07/12/2023 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 14, 2023 - (NASDAQ: VTRS) | NASDAQ:VTRS | Viatris Inc |
| 07/07/2023 | 5:45AM | PR Newswire (US) | VTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023 | NASDAQ:VTRS | Viatris Inc |
| 07/06/2023 | 5:45AM | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 14, 2023 - (NASDAQ: VTRS) | NASDAQ:VTRS | Viatris Inc |
| 06/30/2023 | 5:45AM | PR Newswire (US) | VTRS SHAREHOLDER ALERT: Jakubowitz Law Reminds Viatris Shareholders of a Lead Plaintiff Deadline of July 14, 2023 | NASDAQ:VTRS | Viatris Inc |
| 06/28/2023 | 11:45AM | PR Newswire (US) | Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023 | NASDAQ:VTRS | Viatris Inc |
| 05/30/2023 | 6:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:VTRS | Viatris Inc |
| 05/30/2023 | 6:01PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:VTRS | Viatris Inc |
| 05/30/2023 | 9:00AM | PR Newswire (US) | Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023 | NASDAQ:VTRS | Viatris Inc |